DA Davidson upgraded shares of Procter & Gamble (NYSE:PG – Free Report) from a neutral rating to a buy rating in a research report released on Monday morning, MarketBeat reports. The firm currently has $209.00 price objective on the stock, up from their prior price objective of $160.00. DA Davidson also issued estimates for Procter & Gamble’s Q2 2025 earnings at $1.87 EPS, FY2025 earnings at $7.03 EPS and FY2026 earnings at $7.49 EPS.
A number of other research firms also recently issued reports on PG. Evercore ISI boosted their price target on Procter & Gamble from $180.00 to $183.00 and gave the company an “outperform” rating in a research report on Monday, October 21st. StockNews.com downgraded shares of Procter & Gamble from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Dbs Bank lowered shares of Procter & Gamble from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. DZ Bank upgraded shares of Procter & Gamble from a “hold” rating to a “buy” rating and set a $190.00 price objective for the company in a research note on Thursday, August 29th. Finally, Wells Fargo & Company raised their target price on shares of Procter & Gamble from $188.00 to $190.00 and gave the company an “overweight” rating in a research note on Friday, November 22nd. Eight equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Procter & Gamble has a consensus rating of “Moderate Buy” and an average target price of $180.45.
Get Our Latest Research Report on PG
Procter & Gamble Price Performance
Procter & Gamble (NYSE:PG – Get Free Report) last issued its quarterly earnings results on Friday, October 18th. The company reported $1.93 earnings per share for the quarter, topping analysts’ consensus estimates of $1.90 by $0.03. The company had revenue of $21.74 billion for the quarter, compared to analyst estimates of $21.99 billion. Procter & Gamble had a return on equity of 33.25% and a net margin of 17.07%. The business’s revenue for the quarter was down .6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.83 EPS. Equities analysts predict that Procter & Gamble will post 6.96 earnings per share for the current year.
Procter & Gamble Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Friday, November 15th. Shareholders of record on Friday, October 18th were paid a $1.0065 dividend. The ex-dividend date of this dividend was Friday, October 18th. This represents a $4.03 dividend on an annualized basis and a yield of 2.24%. Procter & Gamble’s payout ratio is currently 69.48%.
Insider Activity at Procter & Gamble
In other news, insider Balaji Purushothaman sold 12,800 shares of the firm’s stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $172.73, for a total transaction of $2,210,944.00. Following the transaction, the insider now directly owns 11,595 shares of the company’s stock, valued at approximately $2,002,804.35. This trade represents a 52.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Susan Street Whaley sold 634 shares of the stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $171.65, for a total transaction of $108,826.10. Following the completion of the transaction, the insider now owns 19,341 shares of the company’s stock, valued at $3,319,882.65. This represents a 3.17 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 35,233 shares of company stock worth $6,024,234 in the last 90 days. 0.18% of the stock is currently owned by company insiders.
Institutional Trading of Procter & Gamble
A number of hedge funds and other institutional investors have recently modified their holdings of PG. Concurrent Investment Advisors LLC grew its position in Procter & Gamble by 4.5% in the third quarter. Concurrent Investment Advisors LLC now owns 94,109 shares of the company’s stock worth $16,300,000 after buying an additional 4,035 shares during the last quarter. Radnor Capital Management LLC bought a new stake in shares of Procter & Gamble during the 3rd quarter worth $5,705,000. Welch Group LLC grew its holdings in shares of Procter & Gamble by 0.9% in the 3rd quarter. Welch Group LLC now owns 323,870 shares of the company’s stock worth $56,094,000 after acquiring an additional 2,990 shares during the last quarter. Swiss National Bank raised its position in shares of Procter & Gamble by 0.6% during the third quarter. Swiss National Bank now owns 7,005,790 shares of the company’s stock worth $1,213,403,000 after purchasing an additional 39,000 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in shares of Procter & Gamble by 67.2% during the second quarter. GAMMA Investing LLC now owns 26,803 shares of the company’s stock valued at $4,420,000 after purchasing an additional 10,777 shares during the last quarter. Institutional investors own 65.77% of the company’s stock.
Procter & Gamble Company Profile
The Procter & Gamble Company engages in the provision of branded consumer packaged goods worldwide. The company operates through five segments: Beauty; Grooming; Health Care; Fabric & Home Care; and Baby, Feminine & Family Care. The Beauty segment offers conditioners, shampoos, styling aids, and treatments under the Head & Shoulders, Herbal Essences, Pantene, and Rejoice brands; and antiperspirants and deodorants, personal cleansing, and skin care products under the Olay, Old Spice, Safeguard, Secret, SK-II, and Native brands.
Read More
- Five stocks we like better than Procter & Gamble
- 3 Monster Growth Stocks to Buy Now
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- 3 REITs to Buy and Hold for the Long Term
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Canadian Penny Stocks: Can They Make You Rich?
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Procter & Gamble Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Procter & Gamble and related companies with MarketBeat.com's FREE daily email newsletter.